MedDRA preferred term

Gamma-glutamyltransferase increased: adverse event reports recording this term

21,704 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

21,704
reports recording the term: 0.1% of all reports; 834
reports, 12 months to June 2026: 796 in the 12 months before; 95.7%
marked serious by the reporter: 57.4% across all reports; 8.6%
record death among outcomes, as reported: 9.1% across all reports

21,704 reports in FDA's adverse event database record the MedDRA term "Gamma-glutamyltransferase increased": 0.1% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

834 reports recorded it in the 12 months to June 2026, close to the 796 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 95.7% are marked serious, 8.6% include death among the outcomes and 46.2% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Gilenya, Methotrexate and Kisqali. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Gilenya	Sphingosine 1-phosphate receptor modulator	649	0.8%
Methotrexate	Folate analog metabolic inhibitor	420	0.2%
Kisqali	Kinase inhibitor	335	1.4%
Letrozole	Aromatase inhibitor	318	1.1%
Cyclophosphamide	Alkylating drug	317	0.2%
Tracleer	Endothelin receptor antagonist	314	0.9%
Paracetamol	—	305	1.1%
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	298	0.6%
Carboplatin	Platinum-based drug	289	0.3%
Tegretol	Mood stabilizer	289	1.7%
Clozaril	Atypical antipsychotic	268	0.6%
Dexamethasone	Corticosteroid	268	0.2%
Prednisone	Corticosteroid	236	0.1%
Rituximab	CD20-directed cytolytic antibody	230	0.1%
Atorvastatin	—	227	0.5%
Acetaminophen	Nonsteroidal anti-inflammatory drug	225	0.3%
Paclitaxel	Microtubule inhibitor	220	0.3%
Cytarabine	Nucleoside metabolic inhibitor	213	0.4%
Humira	—	213	0%
Nivolumab	Programmed death Receptor-1 blocking antibody	209	0.5%
Rebif	Interferon beta	205	0.5%
Lipitor	HMG-CoA reductase inhibitor	200	0.4%
Afinitor	Kinase inhibitor	198	0.6%
Carbamazepine	Mood stabilizer	195	0.9%
Arava	Antirheumatic agent	190	0.6%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Kinase inhibitor	1,994	0.2%	0.1%
Atypical antipsychotic	1,030	0.2%	0%
Corticosteroid	1,022	0.1%	0%
HMG-CoA reductase inhibitor	904	0.4%	0.5%
Nucleoside metabolic inhibitor	865	0.3%	0.2%
Nonsteroidal anti-inflammatory drug	766	0.1%	0%
Sphingosine 1-phosphate receptor modulator	736	0.7%	0.5%
Anti-epileptic agent	702	0.3%	0.1%
Folate analog metabolic inhibitor	610	0.2%	0.2%
Platinum-based drug	562	0.2%	0.3%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.8%163

2 to 112%441

12 to 171.6%353

18 to 4416.1%3,492

45 to 6429.6%6,427

65 to 7414.7%3,196

75 and over11.7%2,549

Age not given23.4%5,083

Patient sex

Female50%10,858

Male42.9%9,314

Not given7.1%1,532

Grey bar: all 20,646,523 reports in the database. 6% of these reports give the United States as the country.

Questions about "Gamma-glutamyltransferase increased"

What does "Gamma-glutamyltransferase increased" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record gamma-glutamyltransferase increased?

21,704 reports through June 2026 (0.1% of all reports), 834 of them in the latest 12 months.

Which drugs appear most often in these reports?

Gilenya (649), Methotrexate (420), Kisqali (335), Letrozole (318) and Cyclophosphamide (317). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.